Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911. [Wikipedia] (en)
|
http://linked.open...generalReferences
| - 1. Ammon, Susanne, et al. "Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing." British journal of clinical pharmacology 48.3 (1999): 317-322. 2. Rowell, F. J., R. A. Seymour, and M. D. Rawlins. "Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites." European journal of clinical pharmacology 25.3 (1983): 419-424. 3. Schmidt, H., et al. "The role of active metabolites in dihydrocodeine effects." International journal of clinical pharmacology and therapeutics 41.3 (2003): 95-106. (en)
|
http://linked.open...gy/drugbank/group
| - approved (en)
- experimental (en)
- illicit (en)
|
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - Dihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/] (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Dihydrocodeine is metabolized to dihydromorphine -- a highly active metabolite with a high affinity for mu opioid receptors. [3] (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Renal elimination and urinary excretion. [1] (en)
|
http://linked.open.../drugbank/synonym
| |
http://linked.open...umeOfDistribution
| - The disposition of dihydrocodeine is described as a two compartment model. [2] (en)
|
http://linked.open...k/foodInteraction
| - Alcohol may enhance CNS depressant effects (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Igor Likhotvorik, "Preparation of dihydrocodeine from codeine." U.S. Patent US06887999, issued May 03, 2005. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Bioavailability is low (approximately 20%) if administered orally. This may be due to poor gastrointestinal absorption. It is also likely due to pre-systemic metabolism by the liver and intestinal wall. [2] The AUCs after oral and intravenous administration are similar (3203ug/l/h and 3401ug/l/h, respectively). [2] Time to peak values are 1.6 and 1.8hours for a 30mg and 60mg dose, respectively. The concentrations achieved were 71.8 ug/1 and 146 ug/1, respectively. [2] (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...rugbank/clearance
| - Plasma clearance is approximately 300ml/min. [2] The pharmacokinetics of dihydrocodeine and active metabolite dihydromorphine have been reported to be linear. [1] The decline in plasma dihydrocodeine concentrations after intravenous administration has been described as bi-exponential, with a sleep decline in the initial 2h following administration, followed by a mono-exponential decline thereafter. Clearance was not dose dependent. [2] (en)
|
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |